Venous thromboembolism - Incidence and risk factors in a defined urban population;Venos tromboembolisme - Insidens og risikofaktorer i Oslo

Tidsskrift for den Norske Laegeforening

Volumn 118, Issue 25, 1998, Pages 3934-3938

  Strekerud, Finn ^a   Johansen, Anne Mette ^a   Abildgaard, Ulrich ^a  

^a AKER UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; FEMALE; HUMAN; INCIDENCE; MALE; MIDDLE AGED; NORWAY; RISK FACTOR; THROMBOEMBOLISM; VEIN THROMBOSIS;

ADOLESCENT; ADULT; AGED; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NORWAY; RISK FACTORS; THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 0032553048     PISSN: 00292001     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Nordstrom M, Lindblad B, Bergqvist D, Kjellstrom T. A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J Intern Med 1992; 232: 155-60.
2. Anderson FA, Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan N A, Jovanovic B et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism; The Worcester study. Arch Intern Med 1991; 151: 933-8.
3. Kierkegaard A. Incidence of acute deep vein thrombosis in two districts. Acta Chir Scand 1980; 146:267-9.
4. Bick RL, Jakway J, Baker W. Deep vein thrombosis: prevalence of etiologic factors and results of management in 100 consecutive patients. Semin Thromb Hemost 1992; 18: 267-74.
5. Koster T, Rosendaal FR, De Ronde H, Briet E. Vandenbroucke JP, Bertina RM. Venous thrombosis due to anticoagulant response to activated protein C: Leiden thrombophilia study. Lancet 1993; 342: 1503-6.
6. Holmstrom M, Lindmarker P, Granqvist S, Johnsson H, Lockner D. A 6-month follow up in 64 patients with acute deep vein thrombosis. Thromb Haemost 1997; 78: 803-7.
7. Holm A, Finnanger B, Hartmann A, Lserum F, Lohren O, Ruud TE et al. Heparin treatment of deep venous thrombosis in 280 patients: symptoms related to dosage. Acta Med Scand 1984; 215:47-53.
8. Folkemengdens storrelse og sammensetning. Statistisk ârbok for Oslo. 96. ârgang. Oslo: Byràdsavdeling for finans og plan, Statistisk kontor, Oslo kommune, 1996.
9. HO Collaborative study of cardiovascular disease and steroid hormone contraception. Venous thromboembolic disease and combined oral contraceptives: results of multicentre case-control studies. Lancet 1995; 346: 1575-82.
10. Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Beruna RM, Rosendaal FR. Increased risk of venous thrombosis in oral contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344: 1453-57.
11. Toglia MR, Weg JG. Venous thromboembolism during pregnancy. N Engl J Med 1996; 335: 108-14.
12. Daly E, Vessey MP, Hawkins MM, Carson JL, Gough P, March S et al. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996; 348: 977-80.
13. Grodstein F, Stampfer MJ, Goldhaber SZ, Manson JE, Colditz GA, Speizer FE et al. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 1996; 348: 983-7.
14. Gutthan SP, Rodriguez LAG, Castellsague J, Oliart AD. Hormone replacement therapy and risk of venous thromboembolism: population based case-control study. BMJ 1997; 314: 796-800.